Gabelli Funds LLC Has $8.29 Million Stock Position in DaVita Inc. (NYSE:DVA)

Gabelli Funds LLC decreased its stake in shares of DaVita Inc. (NYSE:DVA) by 11.3% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 82,500 shares of the company’s stock after selling 10,500 shares during the quarter. Gabelli Funds LLC owned about 0.09% of DaVita worth $8,289,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. Norges Bank bought a new position in shares of DaVita during the 4th quarter worth approximately $116,373,000. Amundi boosted its stake in DaVita by 226.3% in the 4th quarter. Amundi now owns 659,372 shares of the company’s stock valued at $52,592,000 after purchasing an additional 457,285 shares during the period. Wedge Capital Management L L P NC boosted its stake in DaVita by 6,031.9% in the 2nd quarter. Wedge Capital Management L L P NC now owns 366,813 shares of the company’s stock valued at $36,854,000 after purchasing an additional 360,831 shares during the period. Morgan Stanley boosted its stake in DaVita by 37.9% in the 4th quarter. Morgan Stanley now owns 1,232,647 shares of the company’s stock valued at $92,042,000 after purchasing an additional 339,051 shares during the period. Finally, Point72 Asset Management L.P. boosted its stake in DaVita by 912.4% in the 4th quarter. Point72 Asset Management L.P. now owns 338,139 shares of the company’s stock valued at $25,249,000 after purchasing an additional 304,739 shares during the period. Institutional investors and hedge funds own 84.69% of the company’s stock.

DaVita Price Performance

DaVita stock opened at $97.53 on Tuesday. The company has a debt-to-equity ratio of 6.01, a quick ratio of 1.19 and a current ratio of 1.24. DaVita Inc. has a 52 week low of $69.55 and a 52 week high of $116.97. The stock has a market capitalization of $8.90 billion, a P/E ratio of 14.96, a price-to-earnings-growth ratio of 0.63 and a beta of 0.98. The stock has a fifty day moving average of $87.84 and a 200-day moving average of $95.93.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, November 7th. The company reported $2.85 EPS for the quarter, topping analysts’ consensus estimates of $1.92 by $0.93. DaVita had a return on equity of 63.38% and a net margin of 5.11%. The company had revenue of $3.12 billion during the quarter, compared to analysts’ expectations of $3.02 billion. During the same quarter in the previous year, the firm earned $1.45 EPS. DaVita’s revenue was up 5.9% on a year-over-year basis. On average, sell-side analysts expect that DaVita Inc. will post 8.17 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on DVA. Truist Financial reduced their price target on DaVita from $115.00 to $104.00 and set a “hold” rating for the company in a research note on Wednesday, October 11th. StockNews.com assumed coverage on DaVita in a report on Thursday, October 5th. They issued a “buy” rating for the company. UBS Group dropped their price objective on DaVita from $142.00 to $113.00 and set a “buy” rating for the company in a report on Friday. Finally, TheStreet cut DaVita from a “b-” rating to a “c” rating in a report on Monday, October 23rd. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $102.67.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.